Amphastar Pharmaceuticals, Inc.AMPHNASDAQ
Loading
Operating Income Growth Recovery in ProgressRecovering
Percentile Rank64
3Y CAGR-13.5%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-13.5%/yr
vs -23.0%/yr prior
Acceleration
+9.5pp
Accelerating
Percentile
P64
Within normal range
vs 3Y Ago
0.6x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 40.62% |
| Q3 2025 | -39.98% |
| Q2 2025 | 13.12% |
| Q1 2025 | -17.39% |
| Q4 2024 | -20.87% |
| Q3 2024 | 3.32% |
| Q2 2024 | 15.01% |
| Q1 2024 | -11.06% |
| Q4 2023 | -25.73% |
| Q3 2023 | 96.98% |
| Q2 2023 | 10.36% |
| Q1 2023 | -11.63% |
| Q4 2022 | 62.87% |
| Q3 2022 | -6.43% |
| Q2 2022 | 14.85% |
| Q1 2022 | -10.88% |
| Q4 2021 | -2.09% |
| Q3 2021 | 134.55% |
| Q2 2021 | 2.46% |
| Q1 2021 | 257.97% |
| Q4 2020 | -18.14% |
| Q3 2020 | 220.36% |
| Q2 2020 | -139.06% |
| Q1 2020 | 3165.57% |
| Q4 2019 | -110.15% |
| Q3 2019 | 147.07% |
| Q2 2019 | 130.67% |
| Q1 2019 | -305.31% |
| Q4 2018 | -39.41% |
| Q3 2018 | 189.25% |
| Q2 2018 | 71.19% |
| Q1 2018 | -496.03% |
| Q4 2017 | 40.99% |
| Q3 2017 | -229.06% |
| Q2 2017 | 55.63% |
| Q1 2017 | 131.13% |
| Q4 2016 | -177.80% |
| Q3 2016 | -43.88% |
| Q2 2016 | 153.50% |
| Q1 2016 | -71.64% |